Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02313688
What this trial is testing

Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors

Who this might be right for
Stomach NeoplasmsSiewert Type II Adenocarcinoma of Esophagogastric JunctionRecurrence+1 more
West China Hospital 320
Large-scale testing (Phase 3)Study completedNCT02625623
What this trial is testing

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Who this might be right for
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaGastric Cancer Third Line
EMD Serono Research & Development Institute, Inc. 371
Early research (Phase 1)Study completedNCT00004879
What this trial is testing

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Who this might be right for
Colorectal CancerEsophageal CancerKidney Cancer+3 more
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00891878
What this trial is testing

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionEsophageal Cancer
Alliance for Clinical Trials in Oncology 12
Testing effectiveness (Phase 2)Study completedNCT00397904
What this trial is testing

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

Who this might be right for
Esophageal CancerGastric Cancer
Memorial Sloan Kettering Cancer Center 16
Not applicableStudy completedNCT01939275
What this trial is testing

64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the Stomach+10 more
City of Hope Medical Center 8
Not applicableUnknownNCT05053295
What this trial is testing

Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer

Who this might be right for
Relapsed or Advanced Gastric AdenocarcinomaGastro-esophageal Junction Cancer
Gangnam Severance Hospital 20
Testing effectiveness (Phase 2)Study completedNCT00077545
What this trial is testing

3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Who this might be right for
Adenocarcinoma of the EsophagusRecurrent Esophageal CancerStage IV Esophageal Cancer
National Cancer Institute (NCI) 39
Early research (Phase 1)Ended earlyNCT02283359
What this trial is testing

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Who this might be right for
Esophageal CancerGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 3
Testing effectiveness (Phase 2)UnknownNCT03544723
What this trial is testing

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Who this might be right for
Solid TumorLymphoma
MultiVir, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT01612546
What this trial is testing

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

Who this might be right for
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the Stomach+11 more
City of Hope Medical Center 10
Testing effectiveness (Phase 2)Study completedNCT00054457
What this trial is testing

Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

Who this might be right for
Esophageal CancerGastric Cancer
Alliance for Clinical Trials in Oncology 46
Testing effectiveness (Phase 2)Ended earlyNCT02202759
What this trial is testing

MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

Who this might be right for
Adenocarcinoma of the StomachGastroesophageal Junction Expressing Guanylyl Cyclase C
Millennium Pharmaceuticals, Inc. 38
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Study completedNCT00084617
What this trial is testing

Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the Stomach+6 more
National Cancer Institute (NCI) 39
Testing effectiveness (Phase 2)Looking for participantsNCT06587425
What this trial is testing

The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital 50
Testing effectiveness (Phase 2)Study completedNCT02340975
What this trial is testing

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
MedImmune LLC 114
Early research (Phase 1)Active Not RecruitingNCT04007744
What this trial is testing

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8+19 more
Mayo Clinic 36
Testing effectiveness (Phase 2)WithdrawnNCT03704077
What this trial is testing

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerCancer of the StomachStomach Cancer+1 more
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Ended earlyNCT00098527
What this trial is testing

FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the EsophagusAdenocarcinoma of the StomachRecurrent Esophageal Cancer+1 more
National Cancer Institute (NCI) 20
Next Page